Based on the kinetics of interaction between a receptor and G-protein, a myriad of possibilities may result. Two extreme cases are represented by: 1/Collision coupling, where an agonist binds to the free receptor and then the agonist-receptor complex "collides" with the free G-protein. 2/Pre-coupling, where stable receptor/G-protein complexes exist in the absence of agonist. Pre-coupling plays an important role in the kinetics of signal transduction. Odd-numbered muscarinic acetylcholine receptors preferentially couple to G(q/11), while even-numbered receptors prefer coupling to G(i/o). We analyzed the coupling status of the various subtypes of muscarinic receptors with preferential and non-preferential G-proteins. The magnitude of receptor-G-protein coupling was determined by the proportion of receptors existing in the agonist high-affinity binding conformation. Antibodies directed against the C-terminus of the α-subunits of the individual G-proteins were used to interfere with receptor-G-protein coupling. Effects of mutations and expression level on receptor-G-protein coupling were also investigated. Tested agonists displayed biphasic competition curves with the antagonist [(3)H]-N-methylscopolamine. Antibodies directed against the C-terminus of the α-subunits of the preferential G-protein decreased the proportion of high-affinity sites, and mutations at the receptor-G-protein interface abolished agonist high-affinity binding. In contrast, mutations that prevent receptor activation had no effect. Expression level of preferential G-proteins had no effect on pre-coupling to non-preferential G-proteins. Our data show that all subtypes of muscarinic receptors pre-couple with their preferential classes of G-proteins, but only M(1) and M(3) receptors also pre-couple with non-preferential G(i/o) G-proteins. Pre-coupling is not dependent on agonist efficacy nor on receptor activation. The ultimate mode of coupling is therefore dictated by a combination of the receptor subtype and the class of G-protein.

Department of Neurochemistry Institute of Physiology Academy of Sciences of the Czech Republic v v i Prague Czech Republic

Zobrazit více v PubMed

Kroeze WK, Sheffler DJ, Roth BL. G-protein-coupled receptors at a glance. J Cell Sci. 2003;116:4867–4869. PubMed

Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there?. Nat Rev Drug Discov. 2006;5:993–996. PubMed

Hein P, Bünemann M. Coupling mode of receptors and G proteins. Naunyn Schmiedebergs Arch Pharmacol. 2009;379:435–443. PubMed

Shea LD, Neubig RR, Linderman JJ. Timing is everything the role of kinetics in G protein activation. Life Sci. 2000;68:647–658. PubMed

Dell'orco D, Koch K. Biochem J. in press; 2011. A dynamic scaffolding mechanism for rhodopsin and transducin interaction in vertebrate vision. (doi:10.1042/BJ20110871) PubMed

Okuma Y, Reisine T. Immunoprecipitation of alpha 2a-adrenergic receptor-GTP-binding protein complexes using GTP-binding protein selective antisera. Changes in receptor/GTP-binding protein interaction following agonist binding. J Biol Chem. 1992;267:14826–14831. PubMed

Lachance M, Ethier N, Wolbring G, Schnetkamp PP, Hébert TE. Stable association of G proteins with beta 2AR is independent of the state of receptor activation. Cell Signal. 1999;11:523–533. PubMed

Hynes TR, Mervine SM, Yost EA, Sabo JL, Berlot CH. Live cell imaging of Gs and the beta2-adrenergic receptor demonstrates that both alphas and beta1gamma7 internalize upon stimulation and exhibit similar trafficking patterns that differ from that of the beta2-adrenergic receptor. J Biol Chem. 2004;279:44101–44112. PubMed

Hein P, Frank M, Hoffmann C, Lohse MJ, Bünemann M. Dynamics of receptor/G protein coupling in living cells. EMBO J. 2005;24:4106–4114. PubMed PMC

Michal P, Rudajev V, El-Fakahany EE, Dolezal V. Membrane cholesterol content influences binding properties of muscarinic M2 receptors and differentially impacts activation of second messenger pathways. Eur J Pharmacol. 2009;606:50–60. PubMed PMC

Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci. 1989;12:148–151. PubMed

Nobles M, Benians A, Tinker A. Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. Proc Natl Acad Sci U S A. 2005;102:18706–18711. PubMed PMC

Michal P, El-Fakahany EE, Dolezal V. Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins. J Pharmacol Exp Ther. 2007;320:607–614. PubMed

Jakubík J, Janíčková H, El-Fakahany EE, Doležal V. Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy. Br J Pharmacol. 2011;162:1029–1044. PubMed PMC

Fraser CM, Wang CD, Robinson DA, Gocayne JD, Venter JC. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol Pharmacol. 1989;36:840–847. PubMed

Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature. 2008;455:497–502. PubMed

Zhu SZ, Wang SZ, Hu J, el-Fakahany EE. An arginine residue conserved in most G protein-coupled receptors is essential for the function of the m1 muscarinic receptor. Mol Pharmacol. 1994;45:517–523. PubMed

Oldham WM, Hamm HE. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol. 2008;9:60–71. PubMed

Jakubík J, Bačáková L, Lisá V, el-Fakahany EE, Tuček S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci U S A. 1996;93:8705–8709. PubMed PMC

Jakubík J, El-Fakahany EE, Doležal V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. Mol Pharmacol. 2006;70:656–666. PubMed

De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem. 1980;255:7108–7117. PubMed

Gilchrist A, Mazzoni MR, Dineen B, Dice A, Linden J, et al. Antagonists of the receptor-G protein interface block Gi-coupled signal transduction. J Biol Chem. 1998;273:14912–14919. PubMed

Sykes DA, Dowling MR, Charlton SJ. Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol. 2009;76:543–551. PubMed

Qin K, Dong C, Wu G, Lambert NA. Inactive-state preassembly of G(q)-coupled receptors and G(q) heterotrimers. Nat Chem Biol. 2011;7:740–747. PubMed PMC

Kukkonen JP, Näsman J, Akerman KE. Modelling of promiscuous receptor-Gi/Gs-protein coupling and effector response. Trends Pharmacol Sci. 2001;22:616–622. PubMed

Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099–3108. PubMed

Fusion with Promiscuous Gα16 Subunit Reveals Signaling Bias at Muscarinic Receptors

Novel M2 -selective, Gi -biased agonists of muscarinic acetylcholine receptors

Changes in Membrane Cholesterol Differentially Influence Preferential and Non-preferential Signaling of the M1 and M3 Muscarinic Acetylcholine Receptors